iMeds.se

Optinate Septimum

Information för alternativet: Optinate Septimum 35 Mg Filmdragerad Tablett, visa andra alternativ
Document: Optinate Septimum film-coated tablet ENG PL change

Package leaflet: Information for the patient

Optinate Septimum 35 mg film-coated tablets

risedronate sodium


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.


What is in this leaflet

1. What Optinate Septimum is and what it is used for

2. What you need to know before you take Optinate Septimum

3. How to take Optinate Septimum

4. Possible side effects

5. How to store Optinate Septimum

6. Contents of the pack and other information


1. What Optinate Septimum is and what it is used for


What Optinate Septimum is

Optinate Septimum belongs to a group of non-hormonal medicines called bisphosphonates which are used to treat bone diseases. It works directly on your bones to make them stronger and therefore less likely to break.


Bone is a living tissue. Old bone is constantly removed from your skeleton and replaced with new bone.


Postmenopausal osteoporosis is a condition occurring in women after the menopause where the bones become weaker, more fragile and more likely to break after a fall or strain.

Osteoporosis can also occur in men due to a number of causes including ageing and/or a low level of the male hormone, testosterone.


The spine, hip and wrist are the most likely bones to break, although this can happen to any bone in your body. Osteoporosis–related fractures can also cause back pain, height loss and a curved back. Many patients with osteoporosis have no symptoms and you may not even have known that you had it.


What Optinate Septimum is used for

Treatment of osteoporosis in postmenopausal women, even if osteoporosis is severe. It reduces the risk of spinal and hip fractures.


Treatment of osteoporosis in men at high risk of fractures.


2. What you need to know before you take Optinate Septimum


Do not take Optinate Septimum


Warnings and precautions

Talk to your doctor or pharmacist before taking Optinate Septimum:

Your doctor will advise you on what to do when taking Optinate Septimum if you have any of the above.


Children and adolescents

Risedronate sodium is not recommended for use in children below 18 due to insufficient data on safety and efficacy.


Other medicines and Optinate Septimum

Medicines containing one of the following lessen the effect of Optinate Septimum if taken at the same time:

Take these medicines at least 30 minutes after your Optinate Septimum tablet.


Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.


Optinate Septimum with food and drink

It is very important that you do NOT take your Optinate Septimum tablet with food or drinks (other than plain water) so that it can work properly. In particular do not take this medicine at the same time as dairy products (such as milk) as they contain calcium (see section 2, “Other medicines and Optinate Septimum”).

Take food and drinks (other than plain water) at least 30 minutes after your Optinate Septimum tablet.


Pregnancy and breast-feeding

Do NOT take Optinate Septimum if you may be pregnant, are pregnant or planning to become pregnant (see section 2, “Do not take Optinate Septimum”). The potential risk associated with the use of risedronate sodium (active substance in Optinate Septimum) in pregnant women is unknown.

Do NOT take Optinate Septimum if you are breast-feeding (see section 2, “Do not take Optinate Septimum”).

Optinate Septimum should only be used to treat postmenopausal women and men.


Driving and using machines

Optinate Septimum is not known to affect your ability to drive and use machines.


Optinate Septimum contains a small amount of lactose(see section 2, “Warnings and precautions”).


3. How to take Optinate Septimum


Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.


The recommended dose is ONE Optinate Septimum tablet (35 mg of risedronate sodium) once a week.

Choose one day of the week that best fits your schedule. Every week, take the Optinate Septimum tablet on your chosen day.


For your convenience, so that you take your tablet on the right day every week, there is a feature included with the Optinate Septimum pack:

There are boxes/spaces on the back of the blister card. Please mark the day of the week you have chosen to take your Optinate Septimum tablet. Also, write in the dates you will take the tablet.


WHEN to take the Optinate Septimum tablet

Take your Optinate Septimum tablet at least 30 minutes before the first food, drink (other than plain water) or other medicine of the day.

HOW to take the Optinate Septimum tablet

Your doctor will tell you if you need calcium and vitamin supplements, if you are not taking enough from your diet.


If you take more Optinate Septimum than you should

If you or somebody else has accidentally taken more Optinate Septimum tablets than prescribed, drink one fullglass of milkand seek medical attention.


If you forget to take Optinate Septimum

If you have forgotten to take your tablet on your chosen day, take it on the day you remember. Return to taking one tablet once a week on the day the tablet is normally taken.


Do not take a double dose to make up for a forgotten tablet.


If you stop taking Optinate Septimum

If you stop treatment you may begin to lose bone mass. Please talk to your doctor before you consider stopping treatment.


If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


4. Possible side effects


Like all medicines, this medicine can cause side effects, although not everybody gets them.


Stop taking OptinateSeptimum and contact a doctor immediatelyif you experience any of the following:

Symptoms of a severe allergic reaction such as:

Swelling of face, tongue or throat

Difficulties in swallowing

Hives and difficulties in breathing

Severe skin reactions that can include blistering of the skin.


Tell your doctor promptlyif you experience the following side effects:

Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.


However in clinical studies the other side effects that were observed were usually mild and did not cause the patient to stop taking their tablets.


Common side effects (may affect up to 1 in 10 people)


Uncommon side effects (may affect up to 1 in 100 people)


Rare side effects (may affect up to 1 in 1,000 people)


During post-marketing experience, the following have been reported


Rarely, at the beginning of treatment, a patient’s blood calcium and phosphate levels may fall. These changes are usually small and cause no symptoms.


Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V*. By reporting side effects you can help provide more information on the safety of this medicine.


5. How to store Optinate Septimum


Keep this medicine out of the sight and reach of children.


Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.


This medicine does not require any special storage conditions.


Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information


What Optinate Septimum contains

The active substance is risedronate sodium. Each tablet contains 35 mg risedronate sodium, equivalent to 32.5 mg risedronic acid.


The other ingredients are:

Tablet core: lactose monohydrate (see section 2), crospovidone A, magnesium stearate and cellulose microcrystalline.


Film coating: hypromellose, macrogol, hydroxypropylcelluloseand colloidal anhydrous silica, titanium dioxide [E171], iron oxide yellow [E172], iron oxide red [E172].


What Optinate Septimum looks like and contents of the pack

Optinate Septimum 35 mg film-coated tablets are oval light-orange 11.7 x 5.8 mm tablets with the letters “RSN” on one side and “35 mg” on the other side. The tablets are supplied in blister packs of 1, 2, 4, 10, 12 or 16 tablets. Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

[To be completed nationally]


Manufacturer:

Warner Chilcott Deutschland GmbH,

Dr.-Otto-Röhm-Str. 2-4,

64331 Weiterstadt, Germany


This medicinal product is authorised in the Member States of the EEA under the following

names:

Austria: Actonel einmal wöchentlich 35 mg Filmtabletten

Belgium: Actonel 35 mg Wekelijks filmomhulde tabletten,

Actonel 35 mg hebdomadaire comprimé pelliculé,

Actonel 35 mg Wöchentlich Filmtabletten

Cyprus: Actonel OAW / ''μίαφοράτηνεβδομάδα''

Denmark: Optinate Septimum filmovertrukne tabletter

Finland: Optinate Septimum 35 mg kalvopäällysteiset tabletit

France: Actonel 35 mg comprimé pelliculé

Germany: Actonel einmal wöchentlich 35 mg Filmtabletten

Greece: Actonel OAW / ''μίαφοράτηνεβδομάδα''

Hungary: Actonel 35 mg filmtabletta

Iceland: Optinate Septimum 35 mg filmuhúðaðar töflur

Ireland: Actonel Once a Week 35 mg film coated tablets

Italy: Actonel 35 mg compresse rivestite con film

Luxembourg:Actonel 35 mg hebdomadaire comprimé pelliculé

Malta: Actonel “Once a Week” 35 mg film-coated tablet

The Netherlands: Actonel Wekelijks 35 mg, filmomhulde tabletten

Portugal: Actonel 35 mg comprimidos revestidos por película

Spain: Actonel semanal 35 mg comprimidos recubiertos con película

Sweden: OptinateSeptimum 35 mg filmdragerade tabletter

United Kingdom: Actonel Once a Week 35 mg film-coated tablets


This leaflet was last revised in


14 January 2016


Page 6 of 6